TY - JOUR
T1 - Modulation of endothelial prostaglandin synthesis by corticotropin releasing factor and antagonists
AU - Fleisher-Berkovich, Sigal
AU - Rimon, Gilad
AU - Danon, Abraham
N1 - Funding Information:
We wish to thank Dr. Jean Rivier for kindly providing [ d -Phe 12 ]CRF-(12–41) and Dr. Richard Chizzonite, Hoffmann–LaRoche, for the generous gift of interleukin-1α. This work was supported in part by a grant (to A.D.) from the Chief Scientist's Office, Ministry of Health, Israel.
PY - 1998/7/24
Y1 - 1998/7/24
N2 - Corticotropin releasing factor (CRF) is a hypothalamic hormone that also displays autocrine/paracrine roles at peripheral sites. High concentrations of CRF have been identified in endothelial cells and other inflammatory tissues. We investigated the effects of CRF and antagonists in the regulation of prostaglandin synthesis in bovine aortic endothelial cells, and also characterized the binding of CRF in these cells. Interleukin-1α increased prostacyclin (prostaglandin I2) synthesis in endothelial cells and this response to interleukin-1α was abolished by simultaneous exposure to CRF. The effect of CRF on interleukin-1α-induced prostaglandin synthesis was antagonised by the CRF receptor antagonist α-helical CRF-(9-41). In addition, this as well as another CRF receptor antagonist, namely [d-Phe12]CRF-(12-41), when applied alone at low concentrations inhibited the interleukin-1α-induced prostaglandin synthesis similarly to CRF, suggesting partial agonistic action. Binding of [125I]-labeled CRF in endothelial cells was saturable and fitted a two sites model. K(d) for the higher-affinity class of receptors was 0.2±0.02 nM, and B(max) 0.79±0.095 fmol/mg protein. The lower-affinity class of receptors had a K(d) of 1.77±0.14 μM and B(max) 0.97±0.12 fmol/mg protein. These findings suggest a direct role for CRF in the local regulation of inflammation. Copyright (C) 1998 Elsevier Science B.V.
AB - Corticotropin releasing factor (CRF) is a hypothalamic hormone that also displays autocrine/paracrine roles at peripheral sites. High concentrations of CRF have been identified in endothelial cells and other inflammatory tissues. We investigated the effects of CRF and antagonists in the regulation of prostaglandin synthesis in bovine aortic endothelial cells, and also characterized the binding of CRF in these cells. Interleukin-1α increased prostacyclin (prostaglandin I2) synthesis in endothelial cells and this response to interleukin-1α was abolished by simultaneous exposure to CRF. The effect of CRF on interleukin-1α-induced prostaglandin synthesis was antagonised by the CRF receptor antagonist α-helical CRF-(9-41). In addition, this as well as another CRF receptor antagonist, namely [d-Phe12]CRF-(12-41), when applied alone at low concentrations inhibited the interleukin-1α-induced prostaglandin synthesis similarly to CRF, suggesting partial agonistic action. Binding of [125I]-labeled CRF in endothelial cells was saturable and fitted a two sites model. K(d) for the higher-affinity class of receptors was 0.2±0.02 nM, and B(max) 0.79±0.095 fmol/mg protein. The lower-affinity class of receptors had a K(d) of 1.77±0.14 μM and B(max) 0.97±0.12 fmol/mg protein. These findings suggest a direct role for CRF in the local regulation of inflammation. Copyright (C) 1998 Elsevier Science B.V.
KW - CRF (corticotropin releasing factor)
KW - CRF receptor
KW - CRF-(9-41), α-helical
KW - Endothelium
KW - Interleukin-1
KW - [d-Phe]CRF-(12-41)
UR - http://www.scopus.com/inward/record.url?scp=0032563261&partnerID=8YFLogxK
U2 - 10.1016/S0014-2999(98)00416-6
DO - 10.1016/S0014-2999(98)00416-6
M3 - Article
AN - SCOPUS:0032563261
VL - 353
SP - 297
EP - 302
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 2-3
ER -